BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has earned a consensus recommendation of “Buy” from the eight research firms that are currently covering the stock, MarketBeat reports. Eight analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokerages that have covered the stock in the last year is $13.63.
A number of equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Monday, November 20th. Needham & Company LLC reissued a “buy” rating and set a $12.00 price target on shares of BioCryst Pharmaceuticals in a research report on Monday, January 8th.
BioCryst Pharmaceuticals Stock Up 10.0 %
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. Jump Financial LLC increased its stake in BioCryst Pharmaceuticals by 371.5% during the third quarter. Jump Financial LLC now owns 404,913 shares of the biotechnology company’s stock worth $2,867,000 after purchasing an additional 319,037 shares during the period. Kynam Capital Management LP increased its stake in BioCryst Pharmaceuticals by 184.8% during the second quarter. Kynam Capital Management LP now owns 2,848,197 shares of the biotechnology company’s stock worth $20,051,000 after purchasing an additional 1,848,197 shares during the period. Rice Hall James & Associates LLC increased its stake in BioCryst Pharmaceuticals by 21.5% during the third quarter. Rice Hall James & Associates LLC now owns 2,275,638 shares of the biotechnology company’s stock worth $16,112,000 after purchasing an additional 402,674 shares during the period. Quantbot Technologies LP purchased a new stake in BioCryst Pharmaceuticals during the third quarter worth about $454,000. Finally, Bank of Montreal Can purchased a new stake in BioCryst Pharmaceuticals during the second quarter worth about $329,000. Institutional investors and hedge funds own 91.46% of the company’s stock.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
- Five stocks we like better than BioCryst Pharmaceuticals
- Dividend Payout Ratio Calculator
- MarketBeat Week in Review – 2/5 – 2/9
- Following Congress Stock Trades
- Cloudflare results spark analysts reset: 25% upside ahead
- What Makes a Stock a Good Dividend Stock?
- Beyond Nvidia: The hidden stars with 200% earnings growth
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.